ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers-Reference-Cited by-同舟云学术

ENDORSE: a prognostic model for endocrine therapy in estrogen‐receptor‐positive breast cancers

Published:2022-06 Issue:6 Volume:18 Page:
ISSN:1744-4292
Container-title:Molecular Systems Biology
language:en
Short-container-title:Molecular Systems Biology

Author:

Nath Aritro¹^ORCID,Cohen Adam L²,Bild Andrea H¹^ORCID

Affiliation:

1. Department of Medical Oncology and Therapeutics City of Hope Comprehensive Cancer Center Monrovia CA USA

2. Neuro Oncology Program Inova Schar Cancer Institute Fairfax VA USA

Funder

National Cancer Institute

Publisher

EMBO

Subject

Applied Mathematics,Computational Theory and Mathematics,General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Information Systems

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/msb.202110558

Reference70 articles.

1. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

2. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

3. Crosstalk of TGF-β and Estrogen Receptor Signaling in Breast Cancer

4. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

5. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of miRs-497/195 axis possibly confers endocrine therapy resistance via elevated expression of FLT4 and the noncoding RNA MIR503HG;2024-05-17

2. Overcoming Endocrine Resistance of Luminal a Type Breast Cancer by Targeting EPAS-1/Hypoxia Inducible Factor 2α;2024

3. Developing CuS for Predicting Aggressiveness and Prognosis in Lung Adenocarcinoma;Genes;2023-05-08

4. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up;Cancer;2023-01-18

5. Predicting clinical response to everolimus in ER+ breast cancers using machine-learning;Frontiers in Molecular Biosciences;2022-10-11